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SUMMARY
The genetic dependencies of human cancers widely vary. Here, we catalog this heterogeneity and 
use it to identify functional gene interactions and genotype-dependent liabilities in cancer. By 
using genome-wide CRISPR-based screens, we generate a gene essentiality dataset across 14 
human acute myeloid leukemia (AML) cell lines. Sets of genes with correlated patterns of 
essentiality across the lines reveal new gene relationships, the essential substrates of enzymes, and 
the molecular functions of uncharacterized proteins. Comparisons of differentially essential genes 
between Ras-dependent and -independent lines uncover synthetic lethal partners of oncogenic Ras. 
Screens in both human AML and engineered mouse pro-B cells converge on a surprisingly small 
number of genes in the Ras processing and MAPK pathways and pinpoint PREX1 as an AML-
specific activator of MAPK signaling. Our findings suggest general strategies for defining 
mammalian gene networks and synthetic lethal interactions by exploiting the natural genetic and 
epigenetic diversity of human cancer cells.
In Brief
Charting global genetic interaction networks in human cells with CRISPR-based screens uncovers 
key Ras interactors.
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INTRODUCTION
Cancer is a heterogeneous disease encompassing hundreds of distinct subtypes that differ in 
genetic makeup and epigenetic state. Because of this heterogeneity, different cancers rely on 
different pathways for survival as reflected in striking differences in their responses to 
anticancer agents (Barretina et al., 2012; Garnett et al., 2012). CRISPR-based screens make 
it possible to systematically identify the genes required for the survival and proliferation of 
mammalian cells (Gilbert et al., 2014; Koike-Yusa et al., 2014; Shalem et al., 2014; Wang et 
al., 2014). Studies in a small number of human cancer cell lines defined a common set of 
essential genes that participate in basic cellular processes (Hart et al., 2015; Wang et al., 
2015). With a gene essentiality catalog that covers a larger number of cell lines, it should be 
possible to identify genes required in some cancer cells, but not others, and to use these 
differential essentialities to (1) define sets of genes that function together and (2) pinpoint 
the genetic liabilities specific to particular cancer subtypes.
The essentiality pattern of a gene across many cell lines (its “essentiality profile”) should 
help decipher molecular function. Genes that act together (e.g., in a common molecular 
complex or pathway) will likely have similar profiles so that the function of an 
uncharacterized gene can be inferred by comparing its profile with those of other genes. As 
many biological processes impact cell proliferation, this “guilt-by-association” approach 
should be broadly applicable and may circumvent the need for pathway-specific assays. 
Analogous studies have been successful in mapping genetic networks in budding yeast using 
panels of engineered strains with defined lesions in a common genetic background 
(Costanzo et al., 2016; Hughes et al., 2000). As the spectrum of human cancers captures a 
comparatively broader range of cell states, analyses of cancer cell lines may allow for an 
even larger exploration of gene interactions and how they vary across cell types.
A catalog of essential genes across human cancer cell lines should greatly aid efforts to find 
targets for cancer therapy. While sequencing studies of the cancer genome are providing an 
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increasingly complete description of the genetic alterations that accompany tumorigenesis, 
functional studies are needed to assess the contribution of candidate oncogenes to cancer cell 
survival (Boehm and Hahn, 2011; Garraway and Lander, 2013; Lawrence et al., 2014). 
Furthermore, unbiased surveys of gene essentiality can reveal genes that are not mutated but 
are nonetheless critical for optimal cancer cell fitness (Cheung et al., 2011; Cowley et al., 
2014; Kim et al., 2013; Marcotte et al., 2012; Schlabach et al., 2008; Toledo et al. 2015; 
Tzelepis et al. 2016). By comparing essentiality profiles across large numbers of 
genomically characterized cell lines, it should be possible to identify genes selectively 
required in cells carrying a specific mutation (Kaelin, 2005). This synthetic lethality 
paradigm is well illustrated by the interaction between the tumor suppressors BRCA1/2 and 
the poly(ADP-ribose) polymerases (PARPs), two gene families involved in parallel DNA 
repair pathways (Farmer et al., 2005). By exploiting synthetic lethality, it may be possible to 
develop therapies that treat cancers driven by the loss of a tumor suppressor or an activating 
mutation in a gene product that is “undruggable.” A comprehensive gene essentiality dataset 
will also address if synthetic lethal interactions tend to occur between genes acting in the 
same or parallel pathways and how they may be shaped by cellular context.
We perform CRISPR-based genetic screens to generate a comprehensive gene essentiality 
dataset for a panel of genomically characterized acute myeloid leukemia (AML) cell lines. 
Analysis of these data and follow-up work reveals the molecular functions of previously 
unstudied genes and identified new synthetic lethal interactions with mutant Ras, the most 
common human oncogene. It should be possible to apply the approaches we describe to 
systematically map functional gene networks in mammalian cells and identify targetable 
liabilities in human cancers.
RESULTS
Differences in Gene Essentiality Reflect the Distinguishing Characteristics of AML Cell 
Lines
We performed CRISPR-based screens on a panel of 14 human AML cell lines selected from 
the Cancer Cell Line Encyclopedia (Figure 1A; Tables S1, S2, and S3; see the STAR 
Methods) (Barretina et al., 2012). For each gene in each line, we defined its CRISPR score 
(CS) as the average log2 fold-change in the abundance of all single guide (sg)RNAs 
targeting the gene after 14 population doublings. Replicate screens of NB4 cells were well 
correlated and the CS from our screens could predict the essentiality of homologs in S. 
cerevisiae (Figures 1B, S1A, and S1B; see the STAR Methods). Consistent with prior work, 
essential genes highly overlapped between lines and were strongly enriched for roles in 
fundamental cellular processes (Figure 1C). Additionally, differences in gene essentiality 
between lines reflected known characteristics, such as cytokine dependence and 
developmental origin, of each of the lines (Figures S1C–S1F).
We previously demonstrated, and others recently confirmed, that Cas9-mediated cleavage of 
amplified genomic regions elicits a DNA damage response that causes cell death (Aguirre et 
al., 2016; Munoz et al., 2016; Wang et al., 2015). Thus, the low CRISPR scores of genes in 
amplified regions do not necessarily reflect the essentiality of the encoded products and so 
must be removed from datasets prior to further analyses. We devised a sliding window score 
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(SWS) to identify contiguous stretches of the genome enriched for low scoring genes (see 
the STAR Methods). The SWS analysis identified several peaks across the genome of HEL 
cells, all of which corresponded to regions of high-level genomic amplification; the highest 
peak, residing in an amplicon on 9p24.1, contained JAK2, a mutationally activated driver in 
these cells (Figures 1D–1F) (Quentmeier et al., 2006). High SWS peaks were identified in 
several of the other cell lines; the genes within these peaks were also present at high copy 
number (Figures S1G–S1H). Thus, this simple filtering procedure, which does not rely on 
DNA copy number information, can be used to identify genes whose low CS are likely 
artifactual and thus potentially confounding to downstream analyses.
Correlated Gene Essentiality across Cell Lines Reveals Functional Gene Relationships
Genes acting in the same cellular pathway should show similar patterns of essentiality across 
cell lines, raising the possibility that functional gene networks can be mapped through 
correlation-based analysis of gene essentiality profiles (Figure 2A). To obtain biologically 
meaningful gene associations, comparisons must be made between genes showing 
significant differences in essentiality between lines. Therefore, we chose the most variably 
essential genes as a query set and searched for co-essential partners for each of these genes. 
These associations reveal known and novel gene relationships that encompass several types 
of functional interactions.
Many sets of highly correlated genes encoded physically interacting proteins, including 
heterodimers involved in transcription (LDB1 and LMO2), PI3-Kγ signaling (PIK3CG and 
PIK3R5), amino acid transport (SLC7A5 and SLC3A2), and components of two complexes 
in the mTOR pathway, mTORC2 (MAPKAP1, MLST8, and RICTOR) and GATOR1 
(NPRL2, NPRL3, and DEPDC5) (Figures 2B, 2C, and S2A). This analysis also identified 
larger protein complexes; nearly all non-redundant components of the Fanconi anemia DNA 
repair machinery and the GM-CSF receptor pathway clustered tightly together (Figures 2D 
and S2B). Other sets of genes encoded enzymes catalyzing successive reactions in metabolic 
pathways (Figure 2E).
Interestingly, we identified a single case of anti-correlation between the p53 tumor 
suppressor gene (TP53) and its negative regulators (Figure 2F). The sgRNAs targeting TP53 
provided a selective advantage (indicated by positive CS) to cells with wild-type, but not 
mutant, p53. In these same lines, four negative regulators of p53, TERF1, a telomere-binding 
factor; PPM1D, a p53-induced phosphatase; MDM2, an E3 ubiquitin ligase for p53; and 
MDM4, an inhibitor of p53 transactivation, were selectively required, as their loss 
presumably induced p53-mediated cell-cycle arrest or apoptosis (Figure S2C).
The correlation analysis also revealed several unexpected gene relationships. For example, 
the Furin protease cleaves and activates a diverse array of cytokines and growth factor 
receptors, but in our dataset the essentiality of FURIN correlated very highly with that of 
only one its substrates, the insulin-like growth factor receptor (IGF1R), and its adaptor IRS2 
(Bassi et al., 2005) (Figure 2G). This suggests that IGF1R processing may be the only 
essential function of Furin in cells grown in culture.
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We could also examine the opposite problem: identifying enzymes responsible for the 
maturation of a precursor protein. Activation of the transcription factor Nrf-1 (NFE2L1) 
involves retrotranslocation of Nrf-1 into the cytosol via the ER-associated degradation 
(ERAD) pathway, deglycosylation by PNGase (NGLY1) in the ER, and partial proteolytic 
digestion by an unidentified protease (Radhakrishnan et al., 2014). Our dataset showed 
correlated essentiality between NFE2L1, NGLY1, and the endopeptidase DDI2 (Figure 2G). 
These patterns of gene essentiality suggest that DDI2 may be the unknown protease that 
cleaves Nrf-1. Indeed, very recent work in C. elegans indicates that the homolog of DDI2 
(C01G5.6) does act on the worm version Nrf-1 (Lehrbach and Ruvkun, 2016).
Our analysis also predicted associations between genes for which no functional relationship 
has been previously established (Figure 2H). Lastly, several genes of unknown function, 
such as C1orf27 and C17orf89, had correlated essentialities with genes encoding 
components of well-characterized pathways, suggesting that they may represent new 
pathway members. We performed extensive follow-up experiments to determine whether 
this was indeed the case
C1orf27 Interacts with UFSP2 and Is Required for deUFMylation
The essentiality of C1orf27 correlated with (1) the essentiality of several genes encoding 
components of the UFMylation machinery, a ubiquitin-like protein modification system that 
attaches UFM1 to proteins, and (2) UFM1 expression levels (Figures 3A and 3B) (Komatsu 
et al., 2004). Interestingly, prior work in C. elegans reported that homologs of C1orf27 and 
its most closely correlated partner, UFSP2, a deUFMylating enzyme, localize to the ER 
where they directly interact with each other (Chen et al., 2014). We confirmed these findings 
in human embryonic kidney (HEK)-293T cells stably expressing recombinant human 
C1orf27 and UFSP2 (Figures 3C and 3D).
C1orf27 is predicted to have a C-terminal transmembrane anchor, which may serve to tether 
it and UFSP2 to the ER surface (Figure S3A). Consistent with this model, in C1orf27-null 
cells, UFSP2 failed to localize to the ER and instead was dispersed throughout the 
cytoplasm (Figure 3E). We probed lysates of C1orf27 null cells, as well as from cells 
lacking UFM1, UFSP2, and the E1-like UFM1-activating enzyme, UBA5, with an antibody 
that recognizes free and conjugated UFM1 (Figure 3F). As expected, inactivation of UFM1 
or UBA5 led to the complete loss of UFMylation activity. In contrast, loss of C1orf27 or 
UFSP2 led to the accumulation of UFM1-conjugated proteins, consistent with a defect in 
deUFMylation. These results suggest that C1orf27 is an obligate partner of UFSP2 and that 
this interaction is required for the proper localization and activity of UFSP2.
C17orf89 Is an Assembly Factor for Mitochondrial Complex I
C17orf89, clustered with a large group of mitochondrial genes and in HEK293T cells 
C17orf89 co-localized with the mitochondrial marker COX IV (Figures 3G and 3H). Mass 
spectrometric analysis of anti-FLAG-C17orf89 immunoprecipitates revealed an interaction 
with NDUFAF5, a complex I assembly factor, which we confirmed in co-
immunoprecipitation experiments (Figures 3I and S3B). Strikingly, the mitochondrial gene 
cluster contained several complex I assembly factors, with NDUFAF5 being the top hit.
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Loss of C17orf89 specifically destabilized complex I, but not other respiratory chain, 
complexes (Figures 3J and S3C). Consistent with a defect in OXPHOS, C17orf89-null cells 
consumed oxygen at a profoundly reduced rate and required the addition of pyruvate to the 
media to maintain optimal proliferation (Figures 3K and S3D). Importantly, expression of a 
sgRNA-resistant cDNA rescued these phenotypes. These findings indicate that C17orf89 
encodes a component of the complex I assembly machinery and are in agreement with very 
recent work which characterized C17orf89 via a proteomics-based approach (Floyd et al., 
2016).
Identification of Driver Oncogenes Using an Integrative Genomic Approach
Our gene essentiality catalog can also be used to determine whether a cell line carrying a 
specific oncogene is actually dependent on the mutated gene. A cell line might not be 
dependent for several reasons, including that the observed mutation does not actually 
activate the gene, that the oncogene was required for tumor initiation, but not maintenance, 
or that the cell has acquired a bypass mutation. We compiled a list of candidate oncogenes 
altered in each of the cytokine-independent AML cell lines based on publically available 
mutational and cytogenetic data and assessed the contribution of each candidate to cell 
fitness using our essentiality dataset. Overall, this analysis pinpointed key driver events, 
including common oncogenic mutations and rare translocations, in 11 of the 12 lines 
assessed. (As discussed above, HEL cells harbor a recurrent JAK2V617F mutation, but it 
resides in an amplified region and could not be interrogated in our screens.)
Interestingly, we found that even cell lines harboring the same oncogene showed differences 
in dependence. Four of the cell lines carry activating mutations in FLT3, an established 
oncogene in AML; while FLT3 scored as an essential gene in three of these, it did not in 
PL-21 cells, which were also insensitive to quizartinib, a FLT3 inhibitor (Figures 4A and 
S4A) (Quentmeier et al., 2003).
Examination of other alterations in PL-21 revealed an uncommon mutation at codon 146 of 
the KRAS proto-oncogene. Residue 146 lies within the nucleotide-binding pocket of Kras 
and mutation of the corresponding site in Hras enhances its nucleotide exchange activity 
(Feig and Cooper, 1988). Consistent with Ras pathway activation in PL-21, KRAS was 
essential in this line. Two additional lines had mutations in KRAS and three others in 
NRAS. In all cases, the mutant Ras isoform was selectively essential, whereas wild-type Ras 
lines did not require any of the individual Ras isoforms.
Our library includes on average ten sgRNAs tiled across the body of each gene allowing for 
fine-scale analysis of gene fusions. EOL-1 cells harbor a recurrent FIP1L1-PDGFRA fusion 
gene; in these cells, only sgRNAs targeting the fused portion of PDGFRA scored, resulting 
in an atypical, position-dependent pattern of sgRNA depletion (Figure 4B). Translocation 
partners of the KMT2A (MLL) oncogene showed similar patterns in MV4;11 and THP-1 
cells (Figure S4B).
We applied this “partial gene essentiality” signature to search for translocated genes in OCI-
AML2, which harbors no recurrent oncogenic drivers. Remarkably, our analysis uncovered 
RAF1, which encodes c-Raf, a major Ras effector that regulates the MAPK signaling 
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cascade. Consistent with a previous report, RNA sequencing revealed a chimeric transcript 
spanning exon 4 of MBNL1 and exon 5 of RAF1 that results in the production of a 90-kDa 
gene product (Figures 4C and 4D) (Klijn et al., 2015). This unique rearrangement removes 
the N-terminal autoinhibitory domain of c-Raf and likely leads to MAPK pathway 
activation.
Together, these results illustrate how functional data derived from loss-of-function screens 
can be integrated with genomic information to identify and validate driver oncogenes.
Two Independent Screening Approaches Reveal Common Synthetic Lethal Interactions 
with Oncogenic Ras
We also used our data to identify genes that are selectively essential in cell lines carrying 
particular driver mutations—that is, which have synthetic lethal interactions with the 
mutated gene. Such genes will typically not be mutated and thus cannot be reliably detected 
through genome sequencing. They are of significant interest because they may provide drug 
targets in tumors where the cancer-causing genes cannot readily be targeted, for example, in 
those driven by the loss of tumor suppressor genes or by oncogenes that have proven 
difficult to inhibit directly.
Mutations in the Ras family of GTPases (KRAS, NRAS, and, less frequently, HRAS) are 
commonly found in many human cancers, including AML, and are associated with poor 
clinical prognoses (Cox et al., 2014). Ras controls a diverse array of cellular processes 
through many downstream effectors. As each of these effector pathways is implicated in 
various aspects of Ras-driven tumorigenesis across different cellular contexts, it has been 
difficult to dissect the contribution of each pathway to the overall survival and proliferation 
of cancer cells. Furthermore, it is even less clear if Ras hyper-activation may somehow 
confer dependence on other, unrelated cellular pathways. Systematic screening approaches 
have greatly accelerated efforts to find liabilities in Ras-driven cancers (Barbie et al., 2009; 
Luo et al., 2009a). Here, we employed two independent screening strategies to search for 
synthetic lethal partners of oncogenic Ras (Figure 5A).
In our initial approach, we looked for genes that showed differential essentiality across the 
12 cytokine-independent AML cell lines in our panel. Comparisons between the six Ras-
dependent and six Ras-independent revealed five genes that were required only in the 
context of oncogenic Ras. Two genes (RCE1 and ICMT) are involved in the maturation of 
Ras. Two additional genes (RAF1 and SHOC2) are involved in MAPK pathway signaling. 
The final gene, PREX1, did not immediately fit in either category and is discussed later in its 
own section.
Ras is synthesized as an inactive precursor in the cytosol and converted into its mature 
membrane-associated form through three enzymatic steps: (1) prenylation of the CAAX box 
by farne-syltransferase (FTase) or geranylgeranyltransferase I (GGTase I), (2) cleavage of 
the terminal AAX residues by Ras converting enzyme (Rce1), and (3) methylation of the 
terminal cysteine residue by isoprenylcysteine carboxyl methyltransferase (Icmt). FNTB, 
which encodes a subunit of the FTase, was essential in all cell lines screened, suggesting that 
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FTase acts on a universally essential protein (Figure S5A). RCE1 and ICMT, however, did 
show differential essentiality, suggesting that they modify a more restricted set of substrates.
Among the Ras effector genes, RAF1 and SHOC2 were the only two selectively essential in 
all Ras-driven lines. RAF1 encodes c-Raf, a component of the MAPK signaling cascade 
needed for the initiation of Kras-driven lung cancers (Blasco et al., 2011; Karreth et al., 
2011). SHOC2 encodes a leucine-rich repeat-containing protein that serves as a scaffold for 
Ras and c-Raf (Rodriguez-Viciana et al., 2006). Similar to RAF1 and other Ras pathway 
members, mutations in SHOC2 have been identified in patients with Noonan-like syndromes 
(Cordeddu et al., 2009). Loss of SHOC2 reduced MAPK pathway activity in Ras mutant 
SKM-1 cells, but, importantly, not in OCI-AML2 cells in which RAF1 is constitutively 
active (Figure 5B).
In parallel, we devised an isogenic screening approach that did not rely on the use of 
genetically heterogeneous cancer cell lines. For this purpose, we screened Ba/F3 cells, a 
murine pro-B cell line, which we engineered to express oncogenic NRAS (CGN Ba/F3) 
(Figure 5A; Tables S4 and S5; see the STAR Methods). CGN Ba/F3 cells cultured in the 
absence of IL-3 were dependent on Ras/MAPK signaling, but, critically, this dependence 
was relieved by the addition of IL-3. Therefore, we could identify Ras-associated 
vulnerabilities by comparing gene essentiality between these two conditions. Notably, 
because the genetic background of the cells remains fixed in this experiment, differences in 
essentiality can be directly attributed to Ras dependency (Figure S5C).
Replicate screens revealed a common set of genes selectively required in the absence of 
IL-3. Remarkably, Shoc2, Raf1, Rce1, and Icmt all scored in the top 0.1% of all genes 
indicating a very high degree of overlap between the two screening approaches. Additional 
MAPK pathway members (Braf, Rps6ka1, and Mapk1) scored strongly as well. BRAF and 
MAPK1 did show a differential essentiality in the human AML lines but were dispensable in 
some of the mutant Ras lines presumably because they expressed redundant members of 
these kinase families (Figure S5A). We also identified an Nras-specific dependency. After 
methylation by Icmt, Nras, but not the major Kras isoform (Kras-4B), is palmitoylated. 
Golga7/GOLGA7, which encodes a subunit of the palmitoyltransferase, scored in CGN 
Ba/F3 and two of the three mutant NRAS AML lines, but not in any of the mutant KRAS or 
wild-type Ras lines (Swarthout et al., 2005). Other genes, such as the ubiquitin-specific 
peptidase Usp32/USP32, scored strongly in CGN Ba/F3 cells and a subset of the mutant Ras 
AML lines; the biological basis for its selective essentiality remains to be defined.
These two independent screening approaches converged on a restricted set of common 
dependencies required for the survival and proliferation of Ras-driven cancers. Intriguingly, 
the majority of these genes are involved in the maturation of Ras itself and the downstream 
MAPK signaling pathway (Figure 5C).
MAPK Pathway Activation Requires PREX1 in Mutant Ras AML Cells
The top scoring hit from the human AML screen was PREX1, which encodes a Dbl 
homology-pleckstrin homology domain-containing (DH-PH) guanine nucleotide exchange 
factor (GEF) for the Rac GTPases (Figure 6A) (Welch et al., 2002). Oddly, while PREX1 
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scored strongly in all six mutant Ras AML cell lines, it did not score highly in the CGN 
Ba/F3 cells. To begin to understand this difference, we designed a focused sgRNA library 
targeting synthetic lethal candidate and control genes and used it to pro-file: (1) the 12 
cytokine-independent AML lines used in the genome-wide screens; (2) a validation set of 
five additional mutant Ras AML lines; and (3) 11 mutant and 14 wild-type Ras non-AML 
cancer cell lines derived from other hematopoietic lineages (Tables S6, S7, and S8). For all 
12 of the original AML cell lines, the focused sgRNA library screen results showed the 
highest correlation with those from genome-wide screens conducted in the same line (Figure 
S6).
In all cases, the presence of an amplified or mutated allele of KRAS or NRAS correlated 
with dependence on KRAS and NRAS, respectively (Figure 6B). The downstream MAPK 
pathway members, RAF1 and SHOC2, were selectively essential in all the Ras-dependent 
lines as well. The requirement for PREX1, however, differed between the cancer types. 
Whereas PREX1 was selectively essential in both the original and validation sets of AML 
cell lines harboring mutant Ras, there was no difference in PREX1 essentiality between 
wild-type and mutant Ras lines in the other hematological cancer types.
Given the established biochemical function of PREX1, its importance in mutant Ras AML 
cells likely reflects a requirement for Rac pathway activity. Consistent with this possibility, 
Rac1/RAC1 scored as essential in the CGN Ba/F3 cells and to some degree in the human 
AML lines as well (Figures S5A and S5B). To test the importance of the Rac pathway, we 
asked whether forced activation of Rac1 could bypass the requirement for PREX1 by 
screening SKM-1 cells expressing a constitutively active mutant of Rac1 (Rac1G12V) or 
wild-type Rac1. Consistent with our hypothesis, the dependence on PREX1 was relieved in 
Rac1G12V-expressing cells (Figures 6C and 6D).
Previous studies demonstrate that PREX1 can influence MAPK signaling, suggesting that 
like the other screen hits, it may also act on the MAPK pathway (Ebi et al., 2013). To 
examine this possibility, we screened the focused library in SKM-1 cells stably expressing a 
constitutively active mutant of Mek1 (Mek1DD) or wild-type Mek1. As expected, Mek1 
hyper-activation relieved the dependence on the upstream MAPK pathway components, 
KRAS, RAF1, and SHOC2. Critically, Mek1DD expression also bypassed the requirement 
for PREX1, placing it too upstream of Mek1 (Figures 6E and 6F). The Rac GTPases can 
induce MAPK signaling by stimulating the p21-activated kinases (PAKs), which, in turn, 
phosphorylate and activate c-Raf (King et al., 1998). Consistent with this model, Rac1G12V-
expressing cells had hyperactive PAK and MAPK signaling and knockdown of PREX1 
inhibited these pathways in wild-type SKM-1 cells (Figures 6G–6I). Together, these data 
establish PREX1 as a key input for MAPK pathway activation in Ras-driven AML cells.
Lack of Paralog Expression Explains AML-Specific Dependence on PREX1
As PREX1 is highly expressed in normal myeloid cells, we reasoned that it functions as the 
major activator of Rac signaling in AML cells, but that perhaps other GEFs promote Rac 
activity in other cancers. Consistent with this notion, all of the mutant Ras AML lines 
examined expressed PREX1, but only three of the nine non-AML lines did (Figure 7A). 
Strikingly, TIAM1, another DH-PH Rac-GEF, had the opposite expression pattern—it was 
Wang et al. Page 9
Cell. Author manuscript; available in PMC 2018 February 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
absent in all the AML lines but robustly expressed in all but one of the non-AML lines. 
Notably, the one line not expressing TIAM1, NU-DHL-1, expressed high levels of PREX1 
and was the only PREX1-dependent non-AML line (Figure 6B). Though PREX1 and 
TIAM1 share little sequence homology (6% amino acid identity), we posited that they might 
nonetheless be functionally interchangeable. To test this idea, we screened the focused 
library in THP-1 cells stably expressing TIAM1. As compared to the parental line, THP1-
TIAM1 cells have a reduced dependence on PREX1, which showed the greatest change in 
CS of all 132 genes screened (Figures 7B and 7C). Additionally, TIAM1 expression rescued 
the decrease in PAK signaling caused by PREX1 loss (Figure 7D). Thus, we conclude that 
Ras-driven AML cells specifically require PREX1 because it is the only active Rac-GEF 
expressed in this cancer subtype.
While PREX1 may not serve as an ideal target for pharmacological inhibition, our findings 
raise the possibility that AML and non-AML cancers driven by oncogenic Ras may be 
sensitive to inhibition of the group I PAKs (PAK1-3). Using FRAX-597, a small-molecule 
inhibitor of multiple kinases including the group I PAKs, we tested this hypothesis in two 
isogenic cell pairs with differential requirements for Ras signaling: SKM-1 cells expressing 
either Mek1DD or the control protein Rap2A, as well as CGN Ba/F3 cells cultured in the 
presence or absence of IL-3. In both cases, the cells dependent on Ras signaling were more 
sensitive to PAK inhibition than the isogenic control cells even though FRAX-597 inhibits 
many other kinases besides the PAKs (Figure 7E) (Chow et al., 2012). Collectively, these 
results suggest a model in which all Ras-driven cancers require PAK activity in order to fully 
activate MAPK signaling, with each cancer subtype activating the PAKs via distinct 
mechanisms (Figure 7F).
DISCUSSION
An Integrative Genomic Approach Reveals Oncogene Dependency
Cancer genome sequencing efforts have provided an increasingly complete catalog of the 
genes altered during tumor development (Lawrence et al., 2014). Functional studies enable a 
direct assessment of the contribution of each of these genes to cancer cell fitness (Boehm 
and Hahn, 2011; Garraway and Lander, 2013). Together, these complementary approaches 
should accelerate the identification of novel oncogenes and potential therapeutic targets. 
Some cancers are driven by rare events that are difficult to distinguish from random 
mutations and thus require functional analysis to assess the significance of an alteration 
(Berger et al., 2016; Starita et al., 2015; Tsang et al., 2016). For instance, the tiled design of 
our libraries enabled us to identify the essentiality of translocation events including a rare 
inversion involving the RAF1 kinase in OCI-AML2 cells.
However, mutational information alone cannot discriminate between oncogenes required for 
the continued growth of cancer cells from those solely involved in tumor initiation. Even for 
cells harboring activating mutations in the same oncogene, we found differences in 
essentiality (only three of four FLT3 mutant lines required FLT3). Thus, to more accurately 
guide cancer treatment, functional testing of patient tumor cells, should be considered in 
combination with sequence analysis.
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Functional Gene Network Mapping Using Correlated Gene Essentiality Analysis
The natural variability in the genetic and epigenetic makeup across human cancer cell lines 
leads to differences in gene essentiality and so provides a convenient means for defining 
functional gene networks. Even between lines of a single subtype, we found many genes 
with variable essentiality. Reasoning that genes in the same biological pathway should show 
similar patterns of essentiality, we used the CRISPR scores to cluster genes into groups with 
correlated essentiality. Interestingly, the scores of many gene pairs correlated linearly, with 
the different cell lines showing graded, rather than binary levels of requirements for the 
genes. Our analysis uncovered several classes of functional relationships including gene sets 
encoding protein complexes, metabolic pathways, and enzyme-substrate pairs and enabled 
us to determine the molecular functions of uncharacterized genes.
Analysis of other cancer types or across cancer types may reveal additional interactions and 
surveying across media conditions or in the presence of chemical compounds may also yield 
valuable insights. Moreover, we anticipate that more sophisticated analysis of our dataset 
using approaches that can detect multi-way interactions will allow for continued discovery.
With the exception of the genes involved in p53 signaling, the basis of the variable 
essentiality of all other gene clusters remains unclear. Such an understanding will be 
required in order to exploit these pathways for cancer therapy. Similar to efforts to predict 
cancer drug response, integrative approaches may help uncover biomarkers for gene 
essentiality.
Screens in Established Human AML and Engineered Mouse Cell Lines Uncover a Common 
Set of Ras Synthetic Lethal Interactions
We focused on a special case of co-essentiality: synthetic lethality with oncogenic Ras. In 
large part, our study suggests that the development of therapies that selectively impact Ras-
dependent cancer cells will require re-focusing efforts on targeting select components of the 
Ras pathway itself.
Ras, like many small GTPases, undergoes a series of post-translational modifications to 
facilitate interaction with the inner leaflet of the plasma membrane. Efforts to block this 
process have been primarily directed toward inhibition of the initial step of the pathway 
catalyzed by FTase (Cox et al., 2014). However, FTase inhibitors have been ineffective in the 
clinic as Kras and Nras can be geranylgeranylated, an alternative prenylation pathway 
(Whyte et al., 1997). Additionally, our results here and from prior screens conducted in other 
cancer subtypes indicate that FTase is required in all cells. In contrast to FTase, the enzymes 
catalyzing the latter two steps of the Ras processing pathway, Rce1 and Icmt, do display 
synthetic lethality with oncogenic Ras and may thus serve as therapeutic targets.
Our results provide further support for the central role of MAPK signaling in Ras-driven 
cancers and suggest c-Raf as a therapeutic target. The unique requirement for c-Raf, but not 
other Raf kinases, is consistent with only c-Raf being required in lung cancer models driven 
by oncogenic Ras (Blasco et al., 2011; Karreth et al., 2011).
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A mechanistic insight from our study is the critical role of the Rac/PAK signaling axis in 
promoting MAPK activity in mutant Ras cancers. Even though the Rac GTPases activate 
many downstream pathways, we found that forced expression of constitutively active Mek1 
can bypass the requirement for PREX1. The selective essentiality of PREX1 in Ras-driven 
AML, but not in the other cancer types tested, likely reflects the critical role of PREX1 in 
normal myeloid cells. In neutrophils, where PREX1 is highly expressed, host- and pathogen-
derived chemotactic factors trigger activation of the PI3-Kγ and GPCR pathways (Welch et 
al., 2002). This results in the generation of PIP3 and free Gβγ subunits which recruit PREX1 
and stimulate Rac-GEF activity. In AML cells, Gβγ and PIP3 may be similarly required to 
activate PREX1. We note that genes encoding two Gβ subunits (GNB1/2), a Gγ subunit 
(GNG5), a Gβγ-modulator (PDCL), and the catalytic and regulatory subunits of PI3-Kγ 
(PIK3CG/PIK3R5) all showed partial Ras co-dependency (Figure S5A). We hypothesize 
that Ras-driven cancers originating from other cell types rely on other Rac-GEFs, such as 
TIAM1 and VAV1, to activate PAK signaling.
Design of Synthetic Lethal Screens and sgRNA Libraries
The combination of screening approaches employed here provides a guide for the design of 
robust screens for synthetic lethal interactions. As illustrated by the case PREX1 in Ras-
driven AML, genetic interactions with oncogenes may occur in a cell context-dependent 
manner. Thus, it may be sensible to screen lines of a particular cell type or to include enough 
cell lines representing each cancer type. Additionally, screens across isogenic cell lines 
should be employed to eliminate factors that may confound analyses across genetically 
heterogeneous cancer cell lines. Here, we screened Ba/F3 cells expressing oncogenic NRAS 
in the presence and absence of IL-3. This perturbation altered oncogene dependence, but not 
proliferation rate (Figure S5C).
Microarray-based oligonucleotide synthesis enables the rapid generation of focused sgRNA 
libraries for follow-up studies. As such experiments require vastly fewer numbers of cells, 
many additional cell lines can be tested. By using expanded cell line panels representing 
more cancer types, the generality of the interactions can be assessed and with engineered 
panels of lines, epistatic relationships between hit genes defined. Moreover, it may be 
possible to conduct screens using murine cancer models and identify genes that play critical 
roles in vivo.
General Comments on Synthetic Lethality in Cancer
Synthetic lethal interactions in cancer cells can, in principle, occur between several classes 
of genes. The prototypical example is the inactivation of a so-called ‘caretaker’ gene 
involved in the maintenance of genomic stability that leads to dependence on a parallel 
maintenance pathway (Ashworth et al., 2011; Kaelin, 2005). Such interactions may arise 
between genes involved in distinct but functionally overlapping processes, as seen with the 
BRCA and PARP DNA repair pathways, or between highly related and perhaps even 
interchangeable paralogs, such as ARID1A and ARID1B (Farmer et al., 2005). However, 
this paradigm may not apply to Ras and other genes involved in signal transduction. In 
contrast to loss-of-function mutations in caretaker genes, oncogenic mutations in growth 
factor signaling pathways result in hyperactive signaling and, in most cases, render cells 
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dependent on the altered pathway (Luo et al., 2009b). Furthermore, as these mutations act in 
a dominant fashion, they are typically found in the heterozygous state, leaving the wild-type 
allele intact.
Genes and pathways that protect cancer cells from the diverse stresses associated with the 
malignant state represent a second class of potential vulnerabilities. In comparison to their 
normal counterparts, cancer cells rely to a much greater extent on such cytoprotective 
pathways as they experience elevated levels of mitotic, oxidative, proteotoxic, metabolic, 
and DNA damage-related stress (Luo et al., 2009b). While many of these stresses can be 
experimentally induced by the expression of specific oncogenes, they are almost universally 
found in established tumors regardless of genotype (Courtois-Cox et al., 2008). Thus, it is 
unclear whether these liabilities can be linked to any particular oncogene per se or if they 
arise as a secondary consequence of the increased genomic instability and mitotic index 
characteristic of all cancer cells. Indeed, chaperones, such as Hsp90, act as “genetic hubs” 
and show epistasis with hundreds of client proteins, including several oncogenic kinases 
(Whitesell and Lindquist, 2005). More comprehensive studies that compare various 
genetically defined malignant and pre-malignant cells are needed to pinpoint the specific 
features of the oncogenic state that sensitize cells to inhibition of individual stress response 
pathways. Importantly, as full inhibition of many of these pathways is likely to be lethal, 
gene knockdown approaches, such as CRISPRi, may be better suited to interrogate them 
(Gilbert et al., 2014; Horlbeck et al., 2016).
The only consistent differences in gene essentiality between the mutant and wild-type Ras 
cells in our study were in genes closely connected to Ras itself (Ras post-translational 
processing and MAPK signaling). Extensive experimental evidence in Ras-driven cell lines 
and in murine cancer models supports the importance of these pathways. Our data are in 
general agreement with findings from our correlated essentiality analysis—as with other 
pathways and complexes, cells that require Ras also require other genes that act in concert 
with Ras to promote survival and proliferation. We anticipate that screens for synthetic lethal 
partners of other driver oncogenes will uncover similar networks of ancillary genes that may 
serve as attractive targets for therapy. More broadly, through the systematic application of 
CRISPR-based screens, it should be possible to comprehensively identify the acquired 
vulnerabilities of human cancers.
STAR★METHODS
KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Mouse monoclonal anti-HA (clone 6E2) Cell Signaling Technology 2367
Rabbit polyclonal anti-HA Bethyl A190-208A
Rabbit monoclonal anti-FLAG (clone 
D6W5B)
Cell Signaling Technology 14793
Rabbit monoclonal anti-COX IV (clone 
3E11)
Cell Signaling Technology 4850
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REAGENT or RESOURCE SOURCE IDENTIFIER
Total OXPHOS human WB Antibody 
Cocktail
Abcam ab110411
Rabbit polyclonal anti-Raptor EMD Millipore 09-217
Rabbit monoclonal anti-UFM1 [clone 
EPR4264(2)]
Abcam ab109305
Mouse monoclonal anti-GAPDH (clone 
GT239)
GeneTex GTX627408
Rabbit monoclonal anti-PREX1 (clone 
D8O8D)
Cell Signaling Technology 13168
Mouse monoclonal anti-Sur-8 (clone D-8) Santa Cruz sc-514779
Rabbit polyclonal anti-Tiam1 (C-16) Santa Cruz sc-872
Rabbti polyclonal RagC Cell Signaling Technology 3360
Rabbit polyclonal anti-Phospho-PAK1 
(Ser144)/PAK2 (Ser141)
Cell Signaling Technology 2606
Rabbit monoclonal anti-Phospho-PAK2 
(Ser20) [clone EPR658(2)]
Abcam ab76419
Rabbit polyclonal anti-PAK2 Cell Signaling Technology 2608
Rabbit monoclonal anti-Phospho-p44/42 
MAPK (Erk1/2) (Thr202/Tyr204) (clone 
D13.14.4E)
Cell Signaling Technology 4370
Rabbit polyclonal anti-ERK1/2 p44/42 
MAPK (Erk1/2)
Cell Signaling Technology 9102
Rabbit monoclonal anti-Phospho-c-Raf 
(Ser338) (clone 56A6)
Cell Signaling Technology 9427
Rabbit polyclonal anti-c-Raf Cell Signaling Technology 9422
Rabbit monoclonal anti-Phospho-MEK1/2 
(Ser217/221) (clone 41G9)
Cell Signaling Technology 9154
Mouse monoclonal anti-MEK1 (clone 
61B12)
Cell Signaling Technology 2352
Rabbit polyclonal anti-Phospho-PAK1 
(Ser199/204)/PAK2 (Ser192/197)
Cell Signaling Technology 2605
Rabbit polyclonal anti-Phospho-PAK1 
(Thr423)/PAK2 (Thr402)
Cell Signaling Technology 2601
Rabbit monoclonal anti-S6 Kinase (clone 
49D7)
Cell Signaling Technology 2708
Mouse monoclonal anti-UFSP2 (clone G-11) Santa Cruz sc-376084
Goat polyclonal anti-GRP 94 (C-19) Santa Cruz sc-1794
Mouse monoclonal anti-FLAG (clone M2) Sigma-Aldrich F1804
Goat anti-Rabbit IgG-HRP Santa Cruz sc-2054
Goat anti-Mouse IgG-HRP Santa Cruz sc-2055
Mouse monoclonal anti-rabbit IgG 
(Conformation Specific) (clone L27A9) 
(HRP Conjugate)
Cell Signaling Technology 5127
Donkey anti-Goat IgG (H+L) Secondary 
Antibody, Alexa Fluor 488 conjugate
Thermo Fisher Scientific A-11055
Donkey anti-Mouse IgG (H+L) Secondary 
Antibody, Alexa Fluor 488 conjugate
Thermo Fisher Scientific A-21202
Donkey anti-Mouse IgG Secondary 
Antibody, Alexa Fluor 568 conjugate
Thermo Fisher Scientific A-10037
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REAGENT or RESOURCE SOURCE IDENTIFIER
Donkey anti-Rabbit IgG (H+L) Secondary 
Antibody, Alexa Fluor 568 conjugate
Thermo Fisher Scientific A-10042
Donkey anti-Mouse IgG (H+L) Secondary 
Antibody, Alexa Fluor 647 conjugate
Thermo Fisher Scientific A-31571
Chemicals, Peptides, and Recombinant Proteins
Anti-FLAG M2 Affinity Gel Sigma-Aldrich A2220
X-tremeGENE 9 DNA Transfection Reagent Roche 06365787001
TaKaRa Ex Taq DNA Polymerase TaKaRa RR001A
Cell-Tak Cell and Tissue Adhesive CORNING 354240
FLAG peptide (sequence DYKDDDDK) Biopolymers Core, Koch 
Institute
N/A
Sodium pyruvate Sigma-Aldrich 113-24-6
Human GM-CSF Miltenyi Biotec 130-093-862
Recombinant murine IL-3 PeproTech 213-13
FRAX 597 Selleckchem S7271
Ruxolitinib Selleckchem S1378
Selumetinib Selleckchem S1008
Quizartinib LC Laboratories Q-4747
Critical Commercial Assays
XF24 Extracellular Flux Analyzer Seahorse Bioscience N/A
CellTiter-Glo Luminescent Cell Viability 
Assay
Promega G7570
Active Rac1 Detection Kit Cell Signaling Technology 8815
Nucleofector Device Lonza N/A
Cell Line Nucleofector Kit V Lonza 1003
QIAamp DNA Blood Maxi Kit QIAGEN 51192
QIAamp DNA Blood Midi Kit QIAGEN 51183
Deposited Data
Cell line mutational data (Barretina et al., 2012) https://www.broadinstitute.org/ccle
Cell line mutational data (Forbes et al., 2015) http://cancer.sanger.ac.uk/cell_lines
DNA copy number data (Barretina et al., 2012) https://www.broadinstitute.org/ccle
Cell line microarray expression data (Barretina et al., 2012) https://www.broadinstitute.org/ccle
Experimental Models: Cell Lines
OCI-AML5 CCLE ACC-247
TF-1 CCLE ACC-334
697 CCLE ACC-42
HPB-ALL CCLE ACC-483
Jurkat CCLE ACC-282
KE-37 CCLE ACC-46
MOLT-16 CCLE ACC-29
RCH-ACV CCLE ACC-548
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REAGENT or RESOURCE SOURCE IDENTIFIER
SEM CCLE ACC-546
SUP-T1 CCLE ACC-140
Reh CCLE ACC-22
TALL-1 CCLE ACC-521
NALM-6 CCLE ACC-128
NB-4 CCLE ACC-207
MOLM-13 CCLE ACC-554
HEL CCLE ACC-11
PL-21 CCLE ACC-536
MV4;11 CCLE ACC-102
EOL-1 CCLE ACC-386
OCI-AML2 CCLE ACC-99
OCI-AML3 CCLE ACC-582
P31/FUJ CCLE JCRB0091
MonoMac1 CCLE ACC-252
SKM-1 CCLE ACC-547
THP-1 CCLE ACC-16
SHI-1 DSMZ ACC-645
NOMO-1 J. D. Griffin ACC-542
Ba/F3 J. D. Griffin ACC-300
KY821 JCRB JCRB0105
ML-2 DSMZ ACC-15
ML-1 R. Polakiewicz ECACC 88113007
HT CCLE ACC-567
KM-H2 CCLE ACC-8
L-428 CCLE ACC-197
MC116 CCLE ACC-82
Mino CCLE ACC-687
NU-DHL-1 CCLE ACC-583
RL CCLE ACC-613
SU-DHL-4 CCLE ACC-495
U-937 CCLE ACC-5
JJN-3 CCLE ACC-541
KMS-26 CCLE JCRB1187
KE-97 CCLE RCB1435
KMS-28BM CCLE JCRB1192
L-363 CCLE ACC-49
Recombinant DNA
pLenti-Cas9-GFP This paper Addgene 86145
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REAGENT or RESOURCE SOURCE IDENTIFIER
LentiCRISPR-sgC17orf89-1 This paper Addgene 86137
LentiCRISPR-sgC17orf89-3 This paper Addgene 86136
LentiCRISPR-sgC17orf89-2 This paper Addgene 86135
LentiCRISPR-sgUFSP2 This paper Addgene 86134
LentiCRISPR-sgUFM1 This paper Addgene 86133
LentiCRISPR-sgUBA5 This paper Addgene 86132
LentiCRISPR-sgC1orf27-2 This paper Addgene 86131
LentiCRISPR-sgC1orf27-1 This paper Addgene 86130
LentiCRISPR-sgSHOC2-2 This paper Addgene 86129
LentiCRISPR-sgSHOC2-1 This paper Addgene 86128
LentiCRISPR-sgPREX1 This paper Addgene 86127
lentiCRISPR-AAVS1 sgRNA (Wang et al., 2015) Addgene 70661
pMXs3-NRAS G13D This paper Addgene 86144
pMXs3-TIAM1 This paper Addgene 86143
pMXs2-MEK1 DD This paper Addgene 86142
pMXs2-MEK1 This paper Addgene 86141
pMXs2-RAP2A-GFP This paper Addgene 86140
pMXs2-RAC1 G12V This paper Addgene 86139
pMXs2-RAC1 This paper Addgene 86138
pMXs-C17orf89-FLAG This paper Addgene 86126
pMXs-NDUFAF5-HA This paper Addgene 86125
pMXs-RAP2A-GFP This paper Addgene 86124
pMXs-UFSP2-FLAG This paper Addgene 86123
pMXs-HA-C1orf27 This paper Addgene 86122
pRK5-HA-metap2 (Chantranupong et al., 2016) N/A
Genome-wide human sgRNA library This paper and (Wang et al., 
2015)
N/A
Genome-wide murine sgRNA library This paper N/A
Focused human sgRNA library This paper N/A
Sequence-Based Reagents
Primers for Illumina sequencing This paper See the STAR Methods Genome-
wide CRISPR screening
Primers for sgRNA quantification This paper See the STAR Methods Genome-
wide CRISPR screening
Primers for genotyping KRAS This paper See the STAR Methods
Sanger sequencing
Primers for genotyping NRAS This paper See the STAR Methods
Sanger sequencing
Individual sgRNA target sequences This paper See the STAR Methods Vector 
construction
Genome-wide human sgRNA library This paper and Wang et al., 
2015
See Table S2
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REAGENT or RESOURCE SOURCE IDENTIFIER
Genome-wide murine sgRNA library This paper See Table S4
Focused human sgRNA library This paper See Table S7
Software and Algorithms
TopHat version 2.0.13 (Trapnell et al., 2012) http://cole-trapnell-lab.github.io/cufflinks
R version 2.15.1 The R Project https://www.r-project.org/
GSEA (Subramanian et al., 2005) http://software.broadinstitute.org/gsea/
Prism version 6.0.1 GraphPad https://www.graphpad.com
python version 2.6.8 Python software foundation https://www.python.org/
CONTACT FOR REAGENT AND RESOURCE SHARING
Requests for further information and resources may be directed to Lead Contact David M. 
Sabatini (sabatini@wi.mit.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines and Genomic Annotations—ML-1 cells were a gift from R. Polakiewicz of 
Cell Signaling Technology. Ba/F3 and Nomo-1 cells were a gift from J. D. Griffin of the 
Dana Farber Cancer Institute. ML-2 and SHI-1 cells were obtained from the DSMZ cell 
bank; KY-821 cells from the JCRB cell bank; and all other lines from the Cancer Cell Line 
Encyclopedia (CCLE). Genomic information was obtained from the CCLE and from the 
canSAR database. All cell lines obtained from the CCLE, DSMZ and JCRB were subjected 
to STR profiling and mycoplasma testing.
Cell Culture Conditions—All cells were cultured in IMDM (Life Technologies) and 
supplemented with 20% Inactivated Fetal Calf Serum (Sigma), 5 mM glutamine, and 
penicillin/streptomycin. TF-1 and OCI-AML5 cells were supplemented with 5 ng/ml human 
granulocyte-macrophage colony-stimulating factor (GM-CSF) (Miltenyi Biotec). Where 
indicated, Ba/F3 cells were supplemented with 1 ng/ml murine interleukin-3 (IL-3) 
(PeproTech). For pyruvate supplementation experiments, Nomo-1 cells were cultured in 
RPMI (US Biologicals) supplemented with 10% Inactivated Fetal Calf Serum (Sigma), 5 
mM glutamine, and penicillin/streptomycin in the presence and absence of 1 mM sodium 
pyruvate (Sigma).
METHOD DETAILS
Virus Production and Transduction—Pseudotyped virus was produced by co-
transfecting the transfer vector of interest with the VSV-G envelope plasmid and the Delta-
Vpr (for lentivirus production) or Gag-Pol (for retrovirus production) packaging plasmids 
into HEK293T cells using XTremeGene 9 Transfection Reagent (Roche). Culture media was 
changed 12 hr after transfection and the virus-containing supernatant was collected 72 hr 
after transfection and passed through a 0.45 μm filter to eliminate cells. Target cells in 6-well 
tissue culture plates were infected in media containing 8 μg/mL of polybrene (EMD 
Millipore) by centrifugation at 2220 RPM for 45 min. 24 hr after infection, cells were 
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pelleted to remove virus and re-plated in fresh media. When appropriate, cells were 
subsequently selected with antibiotics.
Vector Construction—The retroviral pMXs transfer vector was used to generate cell 
lines stably expressing cDNAs of interest. Several versions of the pMXs backbone vector 
containing different selectable markers were generated for different experiments. For studies 
related to C1orf27 and C17orf89, FLAG-tagged RAP2A-GFP, UFSP2, and C17orf89 and 
HA-tagged C1orf27 and NDUFAF5 were cloned into a vector containing blasticidin 
deaminase via Gibson Assembly (Gibson et al., 2009). To generate isogenic SKM-1 cell 
lines, RAP2A, Rac1WT, Rac1G12V, Mek1WT (encoded by MAP2K1), and Mek1DD 
(MAP2K1S218D;S221D) were cloned into a vector containing blasticidin deaminase and 
TagRFP, pMXs2, via Gibson Assembly. To generate isogenic Ba/F3 and THP-1 cell lines, 
NRASG13D and TIAM1 were cloned into a vector containing turboRFP, pMXs3, via Gibson 
Assembly. To generate the Cas9-GFP expressing lentiviral construct, a version of 
lentiCRISPR-v1 in which the puromycin N-acetyltransferase ORF was replaced with eGFP.
Individual sgRNA constructs targeting were cloned into lentiCRISPR-v1 (sequences 
provided below) as described previously (Cong et al., 2013).
sgUFM1: TCACGCTGACGTCGGACCCA
sgUBA5: AAGCAGCAGAACATACTCTG
sgUFSP2: CCAGCTGCAGGCCTATAGGA
sgC1orf27-1: GAGATTGTGGAATTTCACAG
sgC1orf27-2: CACAACATTACAGTGGATCC
sgC17orf89-1: CACGCACCTGCCGTACGCCG
sgC17orf89-2: TGTCGGCTAACGGAGCGGTG
sgC17orf89-3: CGCGGGAGTTCGAGGCCCTG
sgSHOC2-1: GCAGTCCCTCCCAGCAGAGG
sgSHOC2-2: CAGTTGACCACTCTTCCCAG
sgPREX1: GGGAGACTGCCAGACTCGGG
sgAAVS1: GGGGCCACTAGGGACAGGAT
Generation of Isogenic Cell Lines for CRISPR Screening—For the genome-wide 
isogenic screens using the murine Ba/F3 cell line, cells were transduced with a lentiviral 
construct expressing Cas9-2A-GFP. Single, viable cells were sorted into 96-well plates by 
fluorescence-activated cell sorting (FACS). A sub-clone expressing high levels of GFP, 
termed Cas9-GFP or Ba/F3 CG, was expanded, transduced with a retroviral construct 
expressing NRASG13D-IRES-RFP, and subjected to FACS for RFP positive cells. During 
this procedure, cells were continuously passaged in the presence of IL-3 and maintained at a 
concentration of less than 100,000 per mL to ensure that cells did not become spontaneously 
cytokine-independent. To obtain cytokine-independent cells, IL-3 was withdrawn from the 
culture media, and, after 1 week, the surviving cells were subjected to a second round of 
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FACS for RFP positive cells. The isolated cell population, termed Cas9-GFP NRASG13D or 
CGN Ba/F3, was subsequently maintained in the absence of IL-3.
For screens using the validation library, SKM-1 cells were transduced with retroviral 
constructs expressing Rap2A, Rac1, Rac1G12V, Mek1 (also known as MAP2K1), and 
Mek1DD; selected with and continuously cultured in blasticidin; and subjected to two rounds 
of FACS for RFP positive cells. THP-1 cells were transduced with a retroviral construct 
expressing TIAM1 and subjected to two rounds of FACS for RFP positive cells.
Genome-wide CRISPR Screening—Genome-wide screens for all of the human and 
mouse cell lines was performed as described in (Wang et al., 2015) with minor modifications 
and the entire screening procedure was performed twice in the human NB4 and mouse 
Ba/F3 cells to assess reproducibility. Briefly, for each line, 240 million target cells were 
transduced with the viral pool to achieve an average 1000-fold coverage of the library after 
selection. After 72 hr, 200 million cells were selected with puromycin. An initial pool of 80 
million cells was harvested for genomic DNA extraction from all of the cell lines except for 
THP-1 and TF-1. The remaining cells were passaged every 3 days, and after 14 doublings, a 
final pool of 100 million cells was harvested for genomic DNA extraction using the QIAamp 
DNA Blood Maxi Kit (QIAGEN) sgRNA inserts were PCR amplified using Ex Taq DNA 
Polymerase (Takara) from 50–75 million genome equivalents of DNA from each initial and 
final sample, achieving an average coverage of ~275–400x of the sgRNA library. The 
resultant PCR products were purified and sequenced on a HiSeq 2500 (Illumina) (primer 
sequences provided below) to monitor the change in the abundance of each sgRNA between 
the initial and final cell populations.
Primer sequences for sgRNA quantification
Forward:
AATGATACGGCGACCACCGAGATCTACACGAATACTGCCATTTGTCTCAAGA
TCTA
Reverse:
CAAGCAGAAGACGGCATACGAGATCnnnnnnTTTCTTGGGTAGTTTGCAGTTT
T
(nnnnnn denotes the sample barcode)
Illumina sequencing primer
CGGTGCCACTTTTTCAAGTTGATAACGGACTAGCCTTATTTTAACTTGCTATT
TCTAGCTCTAAAAC
Illumina indexing primer
TTTCAAGTTACGGTAAGCATATGATAGTCCATTTTAAAACATAATTTTAAAAC
TGCAAACTACCCAAGAAA
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Genome-wide sgRNA Library Construction—For genome-wide screens in the human 
AML cell lines, the human sgRNA library generated in (Wang et al., 2015) was used. 
Notably, the gene-targeting sgRNA sequences in our library were optimized for high 
cleavage activity to enable more sensitive and specific detection of cell-essential genes 
(Wang et al., 2015). For more complete coverage of protein-coding genes, a sub-library 
containing 5,401 additional sgRNAs (comprising 499 intergenic control sgRNAs and 4,902 
sgRNAs targeting 497 additional protein-coding genes) were designed, synthesized, and 
cloned into lentiCRISPRv1. In total, the human sgRNA library contained 187,536 constructs 
targeting 18,543 protein-coding genes and 1,504 intergenic and non-targeting control 
sgRNAs.
Using similar guidelines for the design of highly specific and active sgRNAs, a genome-
wide murine library containing 188,509 sgRNAs (comprising 199 intergenic control 
sgRNAs and 188,310 sgRNAs targeting 18,986 protein-coding genes) was designed, 
synthesized, and cloned into pLenti-sgRNA, a lentiviral sgRNA expression vector that does 
not contain Cas9.
Secondary CRISPR Screening—A pooled library containing 6,661 sgRNAs 
(comprising 499 intergenic control sgRNAs and 6,162 sgRNAs targeting 132 control and 
candidate Ras synthetic lethal genes) was designed and cloned into lentiCRISPR-v1. When 
possible, up to 50 sgRNAs were designed for each gene. The validation screening procedure 
was similar to genome-wide screens with minor modifications. 10 million cells were used 
for screening and harvested during the initial and final collections. Genomic DNA was 
extracted using QIAamp DNA Blood Midi Kit (QIAGEN) and 6 million genomic 
equivalents were processed for PCR.
Antibodies—The following antibodies were used for immunoblotting: HA-Tag (6E2) 
Mouse (Cat#2367), DYKDDDDK Tag (D6W5B) (Cat#14793), PREX1 (D8O8D) 
(Cat#13168), RagC (Cat#3360), p-PAK1 (S144)/PAK2 (S141) (Cat#2606), PAK2 
(Cat#2608), p-MAPK (Erk1/2) (T202/Y204) (Cat#4370), MAPK (Erk1/2) (Cat#9102), p-c-
Raf (S338) (56A6) (Cat#9427), c-Raf (Cat#9422), p-MEK1/2 (S217/221) (41G9) 
(Cat#9154), MEK1 (61B12) (Cat#2352), p-PAK1 (S199/204)/PAK2 (S192/197) (Cat#2605), 
p-PAK1 (T423)/PAK2 (T402) (Cat#2601), p70 S6 Kinase (49D7) (Cat#2708), Mouse Anti-
rabbit IgG (Conformation Specific) (L27A9) mAb (HRP Conjugate) (Cat#5127) from Cell 
Signaling Technology. Goat anti-rabbit IgG-HRP (sc-2054), Goat anti-mouse IgG-HRP 
(sc-2055), Sur-8 (D-8) (sc-514779), Tiam1 (C-16) (sc-872) from Santa Cruz; HA Tag 
(A190-208A) from Bethyl, FLAG M2 antibody (F1804) from Sigma-Aldrich; Total 
OXPHOS human WB Antibody Cocktail (ab110411), UFM1 [EPR4264(2)] (ab109305), p-
PAK2 (S20) [EPR658(2)] (ab76419) from Abcam; Raptor (09-217) from EMD Millipore,; 
and GAPDH (GT239) from GeneTex.
The following antibodies were used for immunofluorescence: UFSP2 (G-11) and GRP94 
(C-19) from Santa Cruz; COX IV (3E11), HA-Tag (6E2), FLAG-Tag (D6W5B) from CST; 
FLAG-Tag (M2) from Sigma; and Donkey anti-Goat IgG (H+L) Secondary Antibody Alexa 
Fluor 488 conjugate, Donkey anti-Mouse IgG (H+L) Secondary Antibody Alexa Fluor 488 
conjugate, Donkey anti-Mouse IgG Secondary Antibody Alexa Fluor 568 conjugate, Donkey 
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anti-Rabbit IgG (H+L) Secondary Antibody Alexa Fluor 568 conjugate, Donkey anti-Mouse 
IgG (H+L) Secondary Antibody Alexa Fluor 647 conjugate from Thermo Fisher.
Cell Lysis and Immunoblotting—Cells were rinsed twice with ice-cold PBS and lysed 
with Triton lysis buffer (1% Triton X-100, 20 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1 mM 
EDTA, 1 PhosSTOP Phosphatase Inhibitor Cocktail tablet per 25 mL buffer [Roche], 1 
cOmplete, EDTA-free Protease Inhibitor Cocktail Tablet per 25 mL buffer [Roche]). The 
cell lysates were cleared by centrifugation at 13,000 rpm at 4°C in a microcentrifuge for 10 
min and quantified for protein amount using BCA reagent (Thermo Scientific). Protein 
samples were normalized for protein content, denatured by the addition of Laemmli buffer 
and boiling for 5 min, resolved by SDS-PAGE, and transferred to a polyvinylidene difluoride 
membrane (Millipore). Immunoblots were processed and analyzed according to standard 
procedures and analyzed using chemiluminescence.
Immunoprecipitation Studies—5 million HEK293T cells stably expressing FLAG-
tagged cDNAs were plated in 10 cm culture dishes. For co-immunoprecipitation (co-IP) 
studies, cells were transfected with 3 μg of the indicated plasmids using XTremeGene 9 
Transfection Reagent (Roche) 24 hr after seeding and the cell culture media was changed the 
following day. 72 hr after seeding, cell lysates were prepared as described above. The 
FLAG-M2 affinity gel (Sigma) was washed three times with lysis buffer. 40 μl of a 50/50 
slurry of the FLAG-M2 affinity gel was then added to clarified cell lysates and incubated 
with rotation for 90 min at 4°C. Following IP, the beads were washed three times with lysis 
buffer. For co-IP experiments, immunoprecipitated proteins were denatured by the addition 
of 40 μl of Laemmli buffer and boiling for 5 min and resolved by SDS-PAGE. For FLAG-
C17orf89 mass spectrometry experiments, immunoprecipitated proteins were eluted using 
the FLAG peptide, resolved rom the FLAG-M2 affinity gel, resolved on 4%–12% NuPage 
gels (Invitrogen), and stained with simply blue stain (Invitrogen). Each gel lane was sliced 
into 10–12 pieces and the proteins in each gel slice were digested overnight with trypsin. 
The resulting digests were analyzed by mass spectrometry.
Immunofluorescence—100 thousand HEK293T cells were seeded on 35 mm 
fibronectin-coated glass-bottom dishes (MatTek). 24 hr later, cells were rinsed with PBS, 
fixed with 4% paraformaldehyde in PBS for 15 min, rinsed with PBS again, permeabilized 
with 0.4% Triton X-100 in PBS for 12 min, rinsed with PBS again, and blocked with 10% 
horse serum (HS) for 20 min. Dishes were then incubated with primary antibody in 10% HS 
for 1 hr at RT, rinsed three times with PBS, and incubated with a fluorescent secondary 
antibody diluted 1:400 in 10% HS for 2 hr at RT in the dark. Finally, cells were rinsed three 
times with PBS and on the second wash were incubated with DAPI for 20 min. Dishes were 
imaged on an Axio Observer.Z1 inverted epifluorescence microscope (Zeiss).
Seahorse Analysis—Oxygen consumption of intact cells was measured using an XF24 
Extracellular Flux Analyzer (Seahorse Bioscience). XF24 Cell Culture Microplates 
(Seahorse Bioscience) were coated with Cell-Tak Cell and Tissue Adhesive (Corning), and 
seeded with 180 thousand Nomo-1 cells (100 μl) per well. The plates were centrifuged to let 
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cells adhere to the bottom, placed in an incubator not supplemented with CO2 for 30 min, 
and subsequently analyzed on the XF24 Analyzer.
siRNA Experiments—Nucleofection of siRNAs was performed using the Cell Line 
Nucleofector Kit V on a Nucleofector Device (Lonza) according to the manufacturer’s 
instructions. Briefly, 5 million SKM-1 cells were pelleted and resuspended in 100 μL 
Nucleofector solution and 2 μL of either the ON-TARGETplus PREX1 siRNA SMARTpool 
or the siGENOME Non-Targeting siRNA Pool #1 (100 μM) and trans-fected using the 
V-001 program. Cells were then resuspended in pre-warmed IMDM supplemented with 10% 
IFS to allow for recovery and the same transfection procedure was repeated 24 hr later. 96 hr 
after the initial transfection, cells were lysed and processed for either immunoblotting as 
described above or with the Active Rac1 Detection Kit (Cell Signaling Technology) 
according to the manufacturer’s instructions to determine the cellular levels of active, GTP-
bound Rac1.
RNA Sequencing—Transcriptomic analysis of PL-21 and OCI-AML2 cells was 
performed using a strand-specific RNA sequencing protocol described previously. Briefly, 
total RNA was extracted using the RNeasy Mini kit (QIAGEN). 5 μg of polyA-selected 
RNA was fragmented and dephosphorylated after which an ssRNA adaptor was then ligated. 
Reverse transcription (RT) was performed using a primer complementary to the RNA 
adaptor after which a DNA adaptor was ligated onto the 3′ end of the resulting cDNA 
product. The library was then PCR amplified, cleaned, quantified using a TapeStation 
(Agilent) and sequenced on a HiSeq 2500 (Illumina). Result reads were then mapped to the 
reference human genome (hg19) using TopHat.
Short-Term Proliferation Assays—ATP-based measurements of cellular viability were 
performed by plating cells in 200 μL of media in 96-well plates. The number of cells and 
biological replicates seeded varied depending on the cell line and the duration of the 
experiment. At the indicated times, 40 μL of CellTiter-Glo reagent (Promega) was added to 
each well, mixed for 5 min, after which the luminescence was measured on the SpectraMax 
M5 Luminometer (Molecular Devices). For the drug treatment experiments, FRAX-597, 
Ruxolitinib, and Selumetinib were obtained from Selleckchem and Quizartinib from LC 
Laboratories.
Sanger Sequencing—For a subset of the mutant Ras cell lines used in our study, KRAS 
and NRAS were subjected to sequencing analysis. Briefly, genomic DNA was extracted and 
amplified via PCR (primer sequences listed below) to interrogate hotspots in both genes. 
The PCR products were then purified and sequenced using the Sanger method.
For residues G12, G13, and A18:
KRAS1 forward: AGGCCTGCTGAAAATGACTGAA
KRAS1 reverse: AAAGAATGGTCCTGCACCAG
For residue Q61:
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KRAS2 forward: CTCAGGATTCCTACAGGAAGCA
KRAS2 reverse: CACCTATAATGGTGAATATCTTCAAAT
For residues K117 and A146:
KRAS3 forward: GGACTCTGAAGATGTACCTATGG
KRAS3 reverse: TCAGTGTTACTTACCTGTCTTGT
For residues G12 and G13:
NRAS1 forward: ACAGGTTCTTGCTGGTGTGA
NRAS1 reverse: CACTGGGCCTCACCTCTATG
For residue Q61:
NRAS2 forward: GTGGTTATAGATGGTGAAACCTGT
NRAS2 reverse: TGGCAAATACACAGAGGAAGC
QUANTIFICATION AND STATISTICAL ANALYSIS
Genome-wide CRISPR Screening—Sequencing reads were aligned to the sgRNA 
library and the abundance of each sgRNA was calculated. A small number of sgRNAs in 
both the human and mouse libraries have identical target sequences because they target 
multiple members of the same highly redundant gene family. Reads mapping to these 
sequences are assigned to all matching sgRNAs. As the human sgRNA library is comprised 
of three separate DNA plasmid sub-pools (due to limitations of microarray-based sgRNA 
synthesis), the counts of the sgRNA within each sub-pool are quantile normalized against 
each other for each of the initial and final AML samples. The sgRNA counts from all of the 
initial cell populations of the AML lines and of the two replicate initial Ba/F3 cell 
populations were combined to generate the human and mouse initial reference datasets, 
respectively. For each initial reference dataset, sgRNAs with less than 50 counts were 
removed from downstream analyses. The log2 fold-change in abundance of each sgRNA was 
calculated for final population samples for each of the cell lines after adding a count of one 
as a pseudocount. Gene-based CRISPR scores (CS) were defined as the average log2 fold-
change in the abundance of all sgRNAs targeting a given gene between the initial and final 
cell populations and calculated for all screens. The CS reported for the NB4 cell line and the 
isogenic Ba/F3 experiments was the average of two independent replicate experiments.
Secondary CRISPR Screening—CRISPR gene scores were calculated as with the 
genome-wide screens with slight modifications. sgRNAs with less than 10,00 counts in the 
initial dataset were removed from the downstream analysis and a pseudocount of 10 was 
added prior to the log2 fold-change calculation. Lastly, CRISPR scores were quantile 
normalized across of all the cell lines screened.
Comparative Essentiality Testing—To compare human gene essentiality with yeast 
gene essentiality 1-to-1 human-yeast homologs mappings were obtained from the Ensembl 
Gene release 79 database. Human genes common to the selected genome-wide CRISPR 
screen datasets were used for comparison. Each dataset was ranked by their respective 
scores and used to predict the essentiality of yeast homologs (Giaever et al., 2002). The 
sensitivity and specificity of these predictions were analyzed using receiver operator 
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characteristic (ROC) curves and the area under the ROC curve was used as the performance 
metric.
Copy Number Peak Analysis—The sliding window score (SWS) for a given gene in a 
given cell line was defined as the number of nearby genes with a CS in the lowest 3% of all 
genes in that cell line. For each gene, a window of the 20 nearest ‘upstream’ and 20 nearest 
‘downstream’ flanking genes was chosen for analysis. As some genomic regions contain 
many bona fide essential genes (e.g., histone gene clusters), genes essential in all lines were 
removed prior to the SWS calculation. For this purpose, the average CS of each gene across 
all cell lines was calculated and genes in the lowest 15% were removed. For each of the 
remaining genes, the SWS was calculated in each cell line. Genes with SWS > 12 were 
designated as high SWS genes and removed from the correlated gene essentiality analysis.
Correlated Gene Essentiality Analysis—To maximize the likelihood of identifying 
biologically meaningful relationship between genes, (1) genes essential in most of the cell 
lines, (2) genes only essential in a single line or which display erythroid-specific essentiality 
and (3) genes with low variability in CS across the 14 cell lines were removed from the 
analysis. For (1), genes for which the second lowest CS was less than −1 were removed. For 
(2), to assess if a gene was selectively essential in any single cell line, pairwise Pearson’s 
correlation coefficients were calculated between the CS profile of each gene across the 14 
cell lines and a 14×14 identity matrix. To assess if a gene was selectively essential in the two 
erythroid lines, a Pearson’s correlation coefficient was calculated between the CS profile of 
each gene and a vector containing 14 binary variables in which the two variables 
corresponding to the erythroid lines are set to ‘1’ with the remaining set to ‘0’. If the 
maximum absolute value of any of these coefficients was greater than 0.8, the gene was 
removed. For (3), the variance of the CS profile each gene across the 14 cell lines was 
obtained. The top 2,000 genes showing the highest variance were included in the correlated 
essentiality analysis. Select sets of genes with high correlation were highlighted and/or 
chosen for follow-up validation.
DATA AND SOFTWARE AVAILABILITY
Data Resources—Data resources can be found in Tables S3, S5, and S8. Additional 
sgRNA-level data and custom scripts for analysis of genome-wide screens are available at: 
http://sabatinilab.wi.mit.edu/wang/2017/.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• CRISPR-based screens identify essential genes in 14 human AML cell lines
• Analysis of correlated gene essentiality reveals functional gene networks
• Two independent approaches uncover a restricted set of Ras synthetic lethal 
interactions
• PREX1 and the Rac pathway are critical regulators of MAPK pathway 
activation
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Figure 1. Genome-wide CRISPR Screens for Cell-Essential Genes
(A) Pooled CRISPR-based screening strategy.
(B) CS correlation between cell lines and replicate screens of NB4.
(C) Common cell-essential genes are involved in fundamental biological processes. Gene set 
enrichment analysis was performed on genes ranked by average CS.
(D–F) SWS analysis. (D) High SWS peaks in HEL that (E) correspond to regions of 
genomic amplification. (F) Contiguous region of low CS genes reside in amplicon on 
chromosome 9p24 containing the JAK2 oncogene.
See also Figure S1 and Tables S1, S2, S3.
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Figure 2. Correlated Gene Essentiality across Cell Lines Uncovers Functional Gene 
Relationships
(A) Strategy for identifying functionally related sets of genes.
(B–F) Correlated essentiality of genes encoding (B) obligate heterodimers, (C) members of 
complexes in the mTOR pathway, (D) components of the Fanconi anemia DNA repair 
pathway, (E) enzymes catalyzing successive metabolic reactions, and (F) negative regulators 
of p53 that are negatively correlated with TP53 essentiality. r, Pearson’s correlation 
coefficient.
(G) Top: FURIN protease shows correlated essentiality with its substrate IGF1R and the 
IRS2 signaling adaptor. Bottom: the transcription factor Nrf-1 (encoded by NFE2L1) shows 
correlated essentiality with the NGLY1 deglycosylase and DDI2 peptidase.
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(H) Correlated essentiality of two sets of genes with no known relationship.
See also Figure S2 and Tables S1, S2, S3, S6, S7, and S8.
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Figure 3. Correlated Essentiality Analysis Reveals Function of Two Uncharacterized Genes
(A) Correlated essentiality of C1orf27 with members of the UFMylation pathway.
(B) UFM1 levels correlate with C1orf27 essentiality.
(C) Recombinant C1orf27 and UFSP2 interact. Rap2A and metap2 served as control bait 
and prey proteins. s.e., short exposure. l.e., long exposure.
(D) Micrograph of a HEK293T cell stably expressing FLAG-UFSP2 and HA-C1orf27. 
GRP94 is an ER marker.
(E) C1orf27 is required for the proper localization of UFSP2 in HEK293T cells.
(F) C1orf27 loss results in accumulation of UFMylated proteins. GAPDH served as a 
loading control.
(G) Correlated essentiality of C17orf89 with members of the OXPHOS pathway.
(H) Micrograph of a HEK293T cell stably expressing FLAG-C17orf89. COX IV is a 
mitochondrial marker.
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(I) Recombinant C17orf89 and NDUFAF5 interact. *, non-specific band.
(J and K) C17orf89 loss (J) destabilizes mitochondrial complex I and (K) reduces oxygen 
consumption. Raptor served as a loading control. Error bars represent SD from four replicate 
wells.
Scale bar, 5 μm.
See also Figure S3 and Tables S1, S2, S3.
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Figure 4. Identification of Driver Oncogenes via an Integrative Genomic Approach
(A) Genomic information and gene essentiality data identify driver oncogenes. JAK2 is a 
known driver in HEL cells, but resides in an amplicon and cannot be assessed in our screen.
(B) PDGFRA and RAF1 participate in oncogenic gene fusions. Only gene-fusion-targeting 
sgRNAs are depleted.
(C) RNA sequencing of OCI-AML2 pinpoints a discontinuity in coverage between exons 4 
and 5 of RAF1. PL-21 served as a control.
(D) Immunoblotting using an antibody against the C terminus of c-Raf identifies a 90-kDa 
protein in OCI-AML2. Raptor served as a loading control.
See also Figure S4 and Tables S1, S2, S3.
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Figure 5. Two Independent Screening Approaches Identify Common Synthetic Lethal 
Interactions with Oncogenic Ras
(A) Left: differential gene essentiality analysis of 12 cytokine-independent AML cell lines. 
The three mutant NRAS and three mutant KRAS cell lines are dependent on the mutated 
Ras isoform. The open circle in RAF1 CS plot represents OCI-AML2. Right: Ba/F3 cells 
were transduced with (C)as9-(G)FP and (N)RASG13D to generate the CGN Ba/F3 line. CGN 
cells do not rely on JAK/STAT signaling and are conditionally dependent on the Ras 
pathway as assessed by sensitivity to the JAK and MEK inhibitors, ruxolitinib, and 
selumetinib. Comparisons between CGN cells cultured in the presence and absence of IL-3 
reveals synthetic lethal interactions with oncogenic Ras. Error bars represent SD from six 
replicate wells.
(B) SHOC2 loss reduced MAPK pathway activity in KRAS mutant SKM-1 cells, but not 
RAF1 mutant OCI-AML2 cells. GAPDH served as a loading control.
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(C) Ras synthetic lethal gene candidates converged on pathways functioning up- and 
downstream of Ras.
See also Figure S5 and Tables S1, S2, S3, S4, and S5.
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Figure 6. MAPK Pathway Activation Requires PREX1 in Mutant Ras AML Cells
(A) PREX1 is differentially essential between human AML cell lines with mutant and wild-
type Ras.
(B) Focused library screens in 42 human hematopoietic cancer cell lines. The mutant Ras, 
non-AML cell line in the PREX1 CS plot represented by the open circle is NU-DHL-1 (see 
Figure 7A). *p < 0.05, Welch’s t test.
(C–F) Focused library screens in SKM-1 cells stably expressing (C and D) wild-type and 
constitutively active Rac1 (Rac1G12V) (E and F), wild-type, constitutively active Mek1 
(Mek1DD), and the parental SKM-1 line.
(G) Mek1 activation increases phospho-Erk1/2 levels. Rac1 activation results in increased 
phospho-PAK levels and MAPK pathway activity. SKM-1 Rap2A served as a negative 
control. Raptor and S6K1 were used as loading controls.
(H and I) PREX1 knockdown reduces (H) active Rac1, (I) phospho-PAK, and MAPK 
pathway activity. Raptor and GAPDH served as loading controls. s.e., short exposure. l.e., 
long exposure.
See also Figure S6 and Tables S1, S2, S3, S6, S7, and S8.
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Figure 7. Lack of Paralog Expression Explains PREX1-Dependence in AML
(A) Analysis of PREX1 and TIAM1 expression. RagC was used as a loading control.
(B) Focused library screens in wild-type and TIAM1-overexpressing THP-1 cells.
(C) CRISPR scores from THP-1 TIAM1 cells are compared with those of the parental 
THP-1 cells to calculate the differential CS.
(D) TIAM1 rescues sgPREX1-mediated inhibition of PAK signaling in THP-1 cells. 
GAPDH served as a loading control.
(E) Treatment of isogenic SKM-1 and Ba/F3 cell line pairs with a group I PAK inhibitor 
FRAX-597. Error bars represent SD from ten replicate wells. *p < 0.05, Welch’s t test.
(F) Proposed model of cell-type-specific PREX1 dependence.
SE, short exposure; LE, long exposure.
See also Tables S6, S7, and S8.
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